







Atlas Genet Cytogenet Oncol Haematol. 2012; 16(9)  644 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
HTRA3 (HtrA serine peptidase 3) 
Przemyslaw Glaza, Dorota Zurawa-Janicka, Barbara Lipinska 
Department of Biochemistry, University of Gdansk, Kladki 24, 80-822 Gdansk, Poland (PG, DZJ, BL) 
 
Published in Atlas Database: April 2012 
Online updated version : http://AtlasGeneticsOncology.org/Genes/HTRA3ID45757ch4p16.html 
DOI: 10.4267/2042/47534 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: Prsp, Tasp 
HGNC (Hugo): HTRA3 
Location: 4p16.1 
Local order: Genes flanking HTRA3 in telomere to 
centromere direction: 
- GMPSP1: guanine monophosphate synthetase 
pseudogene 1 
- SH3TC1: SH3 domain and tetratricopeptide repeats 1 
- HTRA3 
- ACOX3: acyl-CoA oxidase 3 
- METTL19: methyltransferase-like 19 
Note 
Deletions and translocations of the 4p16.1 region are 
associated with the development of Wolf-Hirschhorn 
Syndrome (Iwanowski et al., 2011). The neocentromere 
from a giant supernumerary chromosome in the well-
differentiated liposarcoma cell line (94T778) is 
originated from a region at 4p16.1, which shows high 
frequency of AT sequences and contains a long 




The HTRA3 gene encompasses 37350 bases of DNA. 
The coding part is composed of ten exons (Figure 1). 
Transcription 
Two alternatively spliced variants of HTRA3 mRNA 
have been sequenced, a long variant, length of 2543 
bases, and a short form mRNA, length of 1953 bases 
(Figure 1).  
The long HTRA3 variant has an open frame of 1362 
bases and lacks exon 7.  
It encodes a 49 kDa protein of 453 amino acid residues.  
The short form HTRA3 mRNA has an open frame of 
1074 bases, and lacks three exons: 8, 9 and 10. It 
encodes a 38 kDa protein of 357 amino acid residues 
(Nie et al., 2003).  
The 5' promoter region of HTRA3 is methylated in 
some cases of cervical carcinomas but not in normal 
cervix tissues (Ongenaert et al., 2008). Expression of 
HTRA3 is regulated through methylation in the first 
exon.  
This epigenetic modification causes downregulation of 
HTRA3 expression in human lung cancer cell lines.  
Moreover, low levels of HTRA3 expression in primary 
lung tumors strongly correlate with heavy smoking 
history (Beleford et al., 2010a). It was also shown that 
expression of HTRA3 is stimulated through an indirect 
mechanism involving the MEK/ERK pathway in clear 
cell renal carcinoma (Theoleyre et al., 2010). However, 
transcription factors for HTRA3 are unknown. 
Pseudogene 
No pseudogenes have been identified. 
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Figure 1. Localization and schematic organization of the HTRA3 gene on chromosome 4. The numbers indicate the length in kilo 
bases. Green boxes represent exons. Exons present in the long variant of HTRA3 mRNA (A) and in the short form HTRA3 mRNA (B) are 




HtrA3 belongs to the HtrA family of ATP-independent 
serine proteases, homologues of the HtrA serine 
protease from the bacterium Escherichia coli.  
HtrA proteins are very well conserved in evolution. 
Structurally, they are characterized by the presence of a 
trypsin-like protease domain with the catalytic triad 
His-Asp-Ser and at least one PDZ domain at the C-
terminal end. General function of the HtrA proteins s 
the defense against cellular stresses (such as heat 
shock, oxidative stress) causing aberrations in protein 
structure. At least, four human HtrA proteins have be n 
identified. They are involved in important 
physiological processes including maintenance of 
mitochondrial homeostasis, cell death (apoptosis, 
necrosis, anoikis) and cell signaling. Disturbances in 
their functions may contribute to the development of 
several disorders such as cancer, arthritis and 
neurodegenerative disorders (reviewed by Chien et al., 
2009a; Zurawa-Janicka et al., 2010; Clausen et al., 
2011). 
Description 
The open reading frame (ORF) of the long splice 
variant of HTRA3 mRNA encodes a polypeptide of 
453 aa, mass of approximately 49 kDa. The long 
isoform of HtrA3 (HtrA3-L) contains a signal secretory 
peptide at the N-terminus (1-17), a domain with 
homology to the insulin-like growth factor binding 
proteins (29-94 aa) and a Kazal-type inhibitor motif 
(89-126) followed by a serine protease domain (176-
341 aa) with the catalytic triad His191-Asp219-Ser305 
and one PDZ domain (384-440 aa) at the C-terminal 
end.  
Domain with homology to the insulin-like growth 
factor binding proteins and a Kazal-type inhibitor motif 
shares homology with Mac25 protein.  
The PDZ domain mediates specific protein-protein 
interactions (Figure 2). 
The ORF of the short splice variant of HTRA3 mRNA 
encodes a polypeptide of 357 aa, mass of about 38 kDa. 
Contrary to HtrA3-L, the short isoform of HtrA3 
(HtrA3-S) lacks the PDZ domain. Moreover, the last 
seven C-terminal residues of HtrA3-S (APSLAVH) are 
completely different from the corresponding residues in 
HtrA3-L (DWKKRFI) (Figure 2) (Nie et al., 2003). 
Under treatment of lung cancer cell lines with 
chemotherapeutic agents (cisplatin, etoposide) a 
removal of the N-terminal Mac25 domain has been 
observed (Beleford et al., 2010b).  
The proteolytic processing is believed to be an 
autocatalytic process since the catalytically inactive 
mutant did not undergo such modification. Substitution 
of the serine residue belonging to the protease catalytic 
site with alanine abolished autocatalytic degradation 
(Singh et al., 2012). Solely the structure of PDZ 
domain of HtrA3 was determined by the X-ray 
crystallography (Runyon et al., 2008). 
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Figure 2. Domain organization of human HtrA3 protein. Schematic organization of the long (A) and short (B) isoform of HtrA3 is 
presented. S: signal peptide, IB: domain with homology to insulin-like growth factor binding proteins, KM: Kazal type serine protease 
inhibitor motif, PROTEOLYTIC: trypsin-like domain, PDZ: PDZ domain, DWKKRFI/APSLAVH: amino acid residues different in the HtrA3 
variants. The insulin-like growth factor binding domain (IB) and Kazal type inhibitor motif (KM) are homologous to Mac25 protein. Amino 
acid residues of the HtrA3 catalytic triad are marked (numbers indicate the position of the given residue in a polypeptide chain). 
 
The Myosin-9 was identified as a first endogenous 
binding protein of HtrA3 in the placenta (Singh et al., 
2012). 
Expression 
Both variants of HTRA3 transcripts are widely 
expressed in the human body with variable levels in 
different organs (Nie et al., 2003). Reciprocal ratio of 
the long HTRA3 mRNA to short HTRA3 mRNA is 
dependent on the type of tissue. The highest expression 
of HTRA3 was observed in heart tissues and 
reproductive organs (ovary, uterus and placenta) (Nie et 
al., 2003). 
HTRA3 is expressed predominantly in the glandular 
epithelium, endometrium and decidual cells during 
preparation of endometrium for embryo implantation in 
the early pregnancy. The maximal expression of 
placental HTRA3 is observed during the first trimester 
and then it decreases dramatically (Nie et al., 2005; Nie 
et al., 2006a; Li et al., 2011). Placental HtrA3 
expression is negatively regulated through oxygen 
tension in the placenta (Li et al., 2011). It was clearly 
demonstrated that expression of HTRA3 is up-
regulated during folliculogenesis and luteinisation in 
the rhesus monkey ovary (Bowden et al., 2008). These 
data indicate an important role of HTRA3 in placenta 
development and function. 
Transcription of HTRA3 gene is stimulated through an 
indirect mechanism involving the MEK/ERK pathway 
in clear cell renal carcinoma (Theoleyre et al., 2010). In 
vitro transcriptional studies revealed that infection of 
chicken chondrocytes by bacterium Mycoplasma 
synoviae up-regulates of HTRA3 gene as an apoptosis-
like event (Dusanic et al., 2012). 
Beleford with co-workers showed that expression of 
HTRA3 is silenced by cigarette smoke-mediated 
methylation in lung tumors. This epigenetic 
modification increased the resistance of lung cancer 
cell lines to etoposide- and cisplatin-induced 
cytotoxicity (Beleford et al., 2010a). These result 
suggest that cigarette smoke-induced down-regulation 
of HTRA3 could contribute to the development of 
chemoresistant lung cancer. 
Localisation 
HtrA3 is a nuclear-encoded mitochondrial protease 
(Chien et al., 2009b). Localisation of HtrA3 in the 
mitochondrium depends on the presence of Mac25 
domain and is regulated by protease function of HtrA3 
(Beleford et al., 2010b). Processed forms of HtrA3 
have been also found in the cytoplasm (Beleford et al., 
2010b). However, HtrA3 is also classified as a secret d 
protein (Nie et al., 2003). 
Function 
HTRA3 functions as an ATP-independent serine 
protease. 
HtrA3 has been shown to act as an inhibitor of TGF-
beta signaling. HtrA3 binds to several members of the 
TGF-beta proteins family, including BMP4, TGF-
beta1, TGF-beta2, GDF5, and suppresses signal 
transduction mediated by these extracellular cytokines 
(Tocharus et al., 2004). The proteolytic activity of 
HtrA3 is indispensable for this inhibitory function 
(Tocharus et al., 2004). 
HtrA3 plays a significant role during embryo 
implantation and formation of placenta in mammals in 
the early stage of pregnancy (Nie et al., 2005; Nie et 
al., 2006a; Nie et al., 2006b; Bowden et al., 2008). 
Placental HtrA3 is secreted into the maternal 
circulation and distinctly detectable in serum of 
pregnant women in the first trimester (Nie et al., 
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2006a). At this stage of pregnancy cellular and serum 
level of HtrA3 is the highest and then HtrA3 level is 
dramatically down-regulated by an increase of 
placental oxygen tension at 13-14 week of pregnancy 
(Li et al., 2011). HtrA3, due to its proteolytic activity, 
negatively regulates trophoblast invasion during 
placental development (Singh et al., 2010; Singh et al., 
2011). 
HtrA3 is involved in the programmed cell death, 
apoptosis. It has been demonstrated that stable small
hairpin RNA- and epigenetic-mediated down-
regulation of HTRA3 expression attenuates cisplatin- 
and ethoposide-induced cytotoxicity in lung cancer cell
lines while HTRA3 re-expression of proteolytic active 
HtrA3 promotes etopiside and cisplatine cytotoxicity 
(Beleford et al., 2010a, Beleford et al., 2010b). 
Homology 
The HtrA3 protein is evolutionarily conserved among 
mammalian species. 
At the amino acid level homology between human 
HtrA3 and its orthologs from rat and mouse reaches 
92,3 and 92,7 %, respectively. 
At least three paralogs of human HtrA3 have been 
identified: HtrA1 (L56, ORF480, PRSS11, ARMD7), 
HtrA2 (Omi) and HtrA4. HtrA3 shares the 76, 74 and 
72 % homology with HtrA1, HtrA2 and HtrA4, 
respectively. The identity between HtrA3 and its 









Expression of HTRA3 varies according to the tumor 
type. The variable expression of HTRA3 is manifested 
in hematologic malignancies and depends on specific 
molecular alterations. For instance, expression of 
HTRA3 is up-regulated in pro-B Acute Lymphoblastic 
Leukemia with hyperploidy but down-regulated in B-
cell Acute Lymphoblastic Leukemia and acute myeloid 
leukemia (reviewed by Chien et al., 2009a). HTRA3 is 
up-regulated in esophageal adenocarcinoma (Hao et al.,
2006), pancreatic adenocarcinoma (Iacobuzio-Donhue 
et al., 2003) and seminoma (Korkola et al., 2006). In 
contrast, its diminished expression was observed in 
ovarian (Narkiewicz et al., 2008), endometrial 
(Bowden et al., 2006; Narkiewicz et al., 2009) and lung 
cancers (Beleford et al., 2010a; Beleford et al., 2010b).  
In endometrial cancer the HTRA3 mRNA and protein 
levels were reduced with the increasing tumor staging. 
Moreover, a significant negative correlation between 
HtrA3 and TGF-beta1 protein levels found in 
endometrial cancer suggests that HtrA3 is involved in 
regulation of the TGF-beta1 signaling pathway in this 
type of cancer (Narkiewicz et al., 2009). 
It was demonstrated that HtrA3 is involved in the 
induction of apoptosis in response to cytotoxic stress 
induced by chemotherapeutic agents in lung cancer cell 
lines (Beleford et al., 2010b). Resistance of cancer cells 
to cisplatin- and etoposide-mediated cytotoxicity is 
suggested to be a consequence of disturbances in the 
HtrA3 pro-apoptotic activity (Beleford et al., 2010b). 
Oncogenesis 
Several studies argue the involvement of HtrA3 in 
oncogenesis. HtrA3 acts as a proapoptotic protein and 
is suggested to function as a tumor suppressor 
(Beleford et al., 2010a; Beleford et al., 2010b). 
However, variable expression of HTRA3 depending on 
cancer type makes unambiguous definition of the 
HtrA3 role in carcinogenesis difficult. 
HtrA3 involvement in regulation of TGF-beta signalig 
(Tocharus et al., 2004) forms another link between 
HtrA3 and carcinogenesis. At early stages of 
tumorigenesis, TGF-β proteins act as tumor 
suppressors, inhibiting tumor outgrowth, but in 
advanced phases they stimulate tumor progression, 
invasion and metastasis. 
Preeclampsia 
Note 
Li et al. (2011) showed that placental HtrA3 level and 
secretion of the protein into the maternal circulation is 
regulated by oxygen tension in the placental tissue.  
Abnormally high level of HtrA3 in the maternal serum 
at the 13-14 week of gestation is associated with the 
development of preeclampsia (Li et al., 2011). 
Disease 
Preeclampsia is a severe disorder of human pregnancy.  
It is a multifactorial disease characterized by 
hypertension with proteinuria and is responsible for 
about 18% of maternal deaths and up to 40% of fetal
mortality.  
Every year, 8,5 millions cases of preeclampsia are 
reported.  
Defective remodeling of the maternal vessels in the 
early stage of pregnancy is recognized as important 
factors in the initiation of the disorder (Anderson et al., 
2012; Mary et al., 2012). 
Breakpoints 
Note 
No breakpoints described so far. 
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